AUXOTROPHIC RECOMBINANT BCG STRAIN PASTEUR AND USE THEREOF IN THE CONTROL OF HUMAN INFECTIONS CAUSED BY PARASITES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Apr 19, 2012
app pub date -
Mar 10, 2010
filing date -
Mar 11, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to a vaccinal strain of recombinant BCG Mycobacterium bovis expressing the Schistossoma mansoni Sm14 protein (BCG Pasteur ΔleuD/pΔK410-hsp60*-Sm14). The vaccinal strain of the present invention is employed in the control of infections caused by parasites, specially the Schistossoma mansoni. The vaccinal strain is a an auxotrophic strain to leucine amino acid derived from the BCG Pasteur sub-strain complemented to leucine after genetic transformation with the construct pΔK410-hsp60*-Sm14. The efficacy of the BCG Pasteur ΔleuD/pΔK410-hsp60*-Sm14 strain in the control of the Schistossoma mansoni infection based on the recombinant Sm14 antigen in vivo is showed in the present invention.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully